{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Breast+Carcinoma&page=8",
    "query": {
      "condition": "Metastatic Breast Carcinoma",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 2114,
    "total_pages": 212,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Breast+Carcinoma&page=9&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Breast+Carcinoma&page=7&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T16:06:17.969Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03256344",
      "title": "Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Triple Negative Breast Cancer",
        "Metastatic Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Talimogene Laherparepvec",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Atezolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 36,
      "start_date": "2018-03-19",
      "completion_date": "2021-12-03",
      "has_results": true,
      "last_update_posted_date": "2024-05-14",
      "last_synced_at": "2026-10-14T16:06:17.969Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • New York, New York • Stony Brook, New York",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Stony Brook",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03256344"
    },
    {
      "nct_id": "NCT02479230",
      "title": "Type I-Polarized Autologous Dendritic Cell Vaccine With Tumor Blood Vessel Antigen-Derived Peptides in Metastatic Breast Cancer Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "tumor blood vessel antigen peptide-pulsed alpha-type-1 polarized dendritic cell vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Joseph Baar, MD, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2015-07-17",
      "completion_date": "2022-07-01",
      "has_results": false,
      "last_update_posted_date": "2022-11-22",
      "last_synced_at": "2026-10-14T16:06:17.969Z",
      "location_count": 2,
      "location_summary": "Cleveland, Ohio • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02479230"
    },
    {
      "nct_id": "NCT03505164",
      "title": "The Role of suPAR Biomarker in Blood Samples of Breast Cancer Patients During and Post Doxorubicin Chemotherapy: Causative vs. Predictor",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Doxorubicin Adverse Reaction",
        "Cardiomyopathies, Secondary",
        "Breast Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Rush University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 64 Years · Female only"
      },
      "enrollment_count": 42,
      "start_date": "2017-01-17",
      "completion_date": "2020-07-06",
      "has_results": false,
      "last_update_posted_date": "2021-04-27",
      "last_synced_at": "2026-10-14T16:06:17.969Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • Oak Park, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Oak Park",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03505164"
    },
    {
      "nct_id": "NCT07840599",
      "title": "Fit2ThriveMB: Optimization of a Physical Activity Promotion Intervention for Metastatic Breast Cancer Patients",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Metastatic Breast Cancer",
        "Metastatic Breast Cancer (MBC)",
        "Metastatic Breastcancer"
      ],
      "interventions": [
        {
          "name": "Core Intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "EHR Integration (On v. Off)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Weekly Coaching",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Social+ (on v. off)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Static Goal Setting",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Bi-Weekly Coaching",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Highly Tailored Goal Setting",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 224,
      "start_date": "2027-01-01",
      "completion_date": "2031-06-15",
      "has_results": false,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-10-14T16:06:17.969Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07840599"
    },
    {
      "nct_id": "NCT00003236",
      "title": "Chemotherapy in Treating Women With Previously Treated Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "ISIS 3521",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ISIS 5132",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Eastern Cooperative Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 120 Years · Female only"
      },
      "enrollment_count": null,
      "start_date": "1998-07-13",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2023-06-18",
      "last_synced_at": "2026-10-14T16:06:17.969Z",
      "location_count": 6,
      "location_summary": "Chicago, Illinois • Indianapolis, Indiana • Baltimore, Maryland + 2 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003236"
    },
    {
      "nct_id": "NCT00049114",
      "title": "Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Inflammatory Breast Cancer",
        "Stage II Breast Cancer",
        "Stage IIIA Breast Cancer",
        "Stage IIIB Breast Cancer",
        "Stage IIIC Breast Cancer"
      ],
      "interventions": [
        {
          "name": "doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "tipifarnib",
          "type": "DRUG"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "therapeutic conventional surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 62,
      "start_date": "2003-02",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-06-06",
      "last_synced_at": "2026-10-14T16:06:17.969Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00049114"
    },
    {
      "nct_id": "NCT02463032",
      "title": "Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "ER+ and AR+ Breast Cancer"
      ],
      "interventions": [
        {
          "name": "GTx-024",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GTx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 136,
      "start_date": "2015-08",
      "completion_date": "2019-03",
      "has_results": true,
      "last_update_posted_date": "2020-12-09",
      "last_synced_at": "2026-10-14T16:06:17.969Z",
      "location_count": 4,
      "location_summary": "Fort Lauderdale, Florida • Boston, Massachusetts • Billings, Montana + 1 more",
      "locations": [
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Billings",
          "state": "Montana"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02463032"
    },
    {
      "nct_id": "NCT05142800",
      "title": "Screening For BCRL In Targeted Therapy For Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Lymphedema",
        "Lymphedema Arm",
        "Lymphedema of Upper Arm",
        "Lymphedema of Upper Limb",
        "Lymphedema of the Hands",
        "Edema",
        "Edema Arm",
        "Breast Cancer Lymphedema",
        "Breast Cancer Metastatic",
        "Breast Cancer Stage",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Perometer",
          "type": "DEVICE"
        },
        {
          "name": "SOZO device",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 80 Years · Female only"
      },
      "enrollment_count": 261,
      "start_date": "2018-12-13",
      "completion_date": "2026-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-13",
      "last_synced_at": "2026-10-14T16:06:17.969Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05142800"
    },
    {
      "nct_id": "NCT07224464",
      "title": "The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Metastatic Solid Tumors",
        "Stage 4 Cancer"
      ],
      "interventions": [
        {
          "name": "The Sarah Nanotechnology System - intended to deliver thermal energy to malignant cells for the purpose of thermal destruction of these cells in patients with advanced metastatic solid tumors.",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "New Phase Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2025-12-16",
      "completion_date": "2030-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-15",
      "last_synced_at": "2026-10-14T16:06:17.969Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07224464"
    },
    {
      "nct_id": "NCT07121244",
      "title": "A Phase 1 Study of 68Ga-R11228 and 177Lu-R11228 in Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Locoregionally Recurrent Hormone-receptor Positive Breast Cancer",
        "Metastatic Hormone Receptor Positive Breast Cancer"
      ],
      "interventions": [
        {
          "name": "68Ga-R11228",
          "type": "DRUG"
        },
        {
          "name": "177Lu-R11228",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Radionetics Oncology",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2025-10-01",
      "completion_date": "2026-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-13",
      "last_synced_at": "2026-10-14T16:06:17.969Z",
      "location_count": 6,
      "location_summary": "Indianapolis, Indiana • Glen Burnie, Maryland • Princeton, New Jersey + 3 more",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Glen Burnie",
          "state": "Maryland"
        },
        {
          "city": "Princeton",
          "state": "New Jersey"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07121244"
    }
  ]
}